A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer - Related Studies

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

This study has been completed.

Study NCT00001683. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma
		Melanoma
		Neoplasm Metastasis
		Renal Cell Carcinoma

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Renal Cell

3	More general conditions related to this trial
		Adenocarcinoma
		Immune System Diseases
		Immunoproliferative Disorders
		Kidney Diseases
		Kidney Neoplasms
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neoplastic Processes
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas
		Pathologic Processes
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		COL-3

5	Sponsors listed in this trial
		National Cancer Institute (NCI)